Correspondence 0001654954-22-017026 from Monopar Therapeutics (MNPR)
Monopar Therapeutics
Date: Dec. 29, 2022 · CIK: 0001645469 · Accession: 0001654954-22-017026
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268935
Letter
mnpr_corresp
Monopar Therapeutics Inc.
Skokie Blvd., Suite 350
Wilmette, Illinois 60091
December 29, 2022
VIA EDGAR
US Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
Re: Monopar Therapeutics Inc.
Registration Statement on Form S-3
File No. 333-268935
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Monopar Therapeutics Inc. (the “Company”) hereby respectfully requests that the above-referenced Registration Statement be declared effective at 9:00 a.m., Eastern time, on January 4, 2023 or as soon thereafter as practicable, or such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance.
Please contact John Harrington of Baker & Hostetler LLP at (216) 861-6697 with any questions regarding the foregoing and to confirm the effectiveness of the Registration Statement.
Very
truly yours,
Monopar
Therapeutics Inc.
Show Raw Text
CORRESP 1 filename1.htm mnpr_corresp Monopar Therapeutics Inc. 1000 Skokie Blvd., Suite 350 Wilmette, Illinois 60091 December 29, 2022 VIA EDGAR US Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Monopar Therapeutics Inc. Registration Statement on Form S-3 File No. 333-268935 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Monopar Therapeutics Inc. (the “Company”) hereby respectfully requests that the above-referenced Registration Statement be declared effective at 9:00 a.m., Eastern time, on January 4, 2023 or as soon thereafter as practicable, or such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance. Please contact John Harrington of Baker & Hostetler LLP at (216) 861-6697 with any questions regarding the foregoing and to confirm the effectiveness of the Registration Statement. Very truly yours, Monopar Therapeutics Inc. By: /s/ Chandler D. Robinson Chandler D. Robinson Chief Executive Officer